CareDx (CDNA) Tops Q4 EPS by 26c; Offers FY23 Revenue Guidance

CareDx (NASDAQ: CDNA) reported Q4 EPS of ($0.07), $0.26 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $82.4 million versus the consensus estimate of $81.67 million.

GUIDANCE:

CareDx sees FY2023 revenue of $328-338 million, versus the consensus of $321 million.

For earnings history and earnings-related data on CareDx (CDNA) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c